What type of study is this?

This is a Meta-Analysis study (also classified as: Systematic Review).

December 8, 2025BloodOpen Access

Efficacy and safety of low-dose vs. standard-dose direct oral anticoagulants for secondary prevention of venous thromboembolism: A systematic review and meta-analysis

View Full Paper

Ask AI

Bookmark

Authors

Systematic review finds reduced-dose DOACs lower major bleeding risk in patients with venous thromboembolism, suggesting a safer alternative.

Reduced-dose DOACs significantly lower major bleeding risk while maintaining efficacy for venous thromboembolism prevention.
In a meta-analysis of five RCTs with 8,781 patients, odds ratios indicated similar rates of recurrent VTE between doses.
Randomized controlled trials compared reduced-dose apixaban and rivaroxaban to standard doses over at least 12 months.
Findings highlight the need for further research to identify the optimal populations for reduced-dose anticoagulation.

Dan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Systematic review finds reduced-dose DOACs lower major bleeding risk in patients with venous thromboembolism, suggesting a safer alternative.

Reduced-dose DOACs significantly lower major bleeding risk while maintaining efficacy for venous thromboembolism prevention.
In a meta-analysis of five RCTs with 8,781 patients, odds ratios indicated similar rates of recurrent VTE between doses.
Randomized controlled trials compared reduced-dose apixaban and rivaroxaban to standard doses over at least 12 months.
Findings highlight the need for further research to identify the optimal populations for reduced-dose anticoagulation.

Dan et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark